Explore the Agenda
8:00 am Registration & Coffee
8:50 am Chair’s Opening Remarks
Using Clinical Learnings to Guide Next‑Generation TCR Innovation & Accelerate Progress
9:00 am C-Level Fireside Chat: Reflecting on Lessons from TCR Therapies to Drive Next-Generation Strategies
- Identifying pivotal learnings that can sharpen development strategies and accelerate stronger clinical outcomes
- Framing actionable insights that translate early proof-of-concept gains into durable, real-world clinical impact
- Exploring critical knowledge gaps and defining high-value priorities that can shape the next-generation of TCR innovations
10:00 am Expanding the Potential of TCR-Based T-Cell Engagers into Infectious Diseases
- Sharing early clinical data on TCR-based bispecific molecules developed to treat HBV and HIV
- Analyzing the pharmacokinetics and pharmacodynamics associated with this mechanism of action
- Highlighting the differences from oncology that emerge due to a lack of suppressive tumor microenvironment
10:30 am Delivering Transformational Benefit with TCR-Based Therapies for PRAME Positive Cancers
- Demonstrating first-generation autologous TCR therapy Anzu-Cel achieving 50-60% durable responses in melanoma
- Advancing second-generation efficacy enhanced PRAME TCRs into ovarian and endometrial cancers and the prospect of tissue agnostic expansion
- Bispecific TCR approaches to maximize clinical impact while addressing development and scalability challenges
11:00 am Morning Break & Speed Networking
Integrating Machine Learning & Advanced Screening for Safer Affinity Maturation
12:00 pm Accelerating Affinity Maturation with AI & Machine Learning to Shorten Development Timelines & Improve Precision
- Exploring how AI-driven design can shorten traditional affinity maturation cycles and reduce experimental burden
- Questioning whether current AI tools can reliably predict TCR-peptide-HLA interactions
- Defining what success looks like for AI in TCR engineering and the data needed to prove clinical relevance
12:30 pm Building Next-Generation TCR-TCEs Through High-Titer Expression & Optimized Affinity Maturation
- Achieving high-titer CHO production of soluble TCRs and TCR-TCEs using the WuXian Transient™ expression system
- Optimizing TCR affinity maturation from phage libraries to routinely improve KD by ~10,000-fold (from 10-100 μM)
- Integrating high-throughput expression and affinity maturation to efficiently generate building blocks for next-generation TCR-TCE therapeutics
1:00 pm Lunch Break & Networking
Driving Innovation with TCR Mimic Antibodies to Expand Therapeutic Possibilities
2:00 pm Next-Generation HLA/Peptide-Targeted Therapies: Lessons Learned from Comparing TCR-T Versus TCR Mimetic CAR-T
- State-of-the-art techniques for discovering tumor-specific HLA/peptide targets and technologies for generating TCRs and TCR mimetic antibodies
- Directly compare and contrast TCR-T versus TCR mimetic CAR-T cells in vitro and in vivo
- Engineering T-cells and combinations with biologics for optimal deployment of HLA/ peptide-targeted therapies in the clinic
2:30 pm Applying TCR Mimic Antibodies in T-Cell Therapy to Achieve Durable & Persistent Clinical Responses
- Sharing developments in an ongoing phase 1 trial and key learnings from the clinic
- Explaining how TCR mimic armed T-cell therapy enables dual activation of CD4 and CD8 T-cells
- Discuss why CD4 engagement is critical for long-term efficacy
3:00 pm Session Reserved for Alloy Therapeutics
3:30 pm Afternoon Break & Poster Session
Achieving Both Efficacy & Commercial Viability with New Innovations in TCR-Based Therapies
4:30 pm Balancing Personalization & Scalability in Next-Generation TCR Therapies to Expand Patient Access
- Examining how personalization can sharpen therapeutic precision while introducing cost and complexity trade-offs critical for strategic planning
- Comparing personalized and shared TCR strategies to identify the optimal balance of precision, accessibility, and real-world patient reach
- Designing regulatory and manufacturing pathways that enable scalable, compliant use of personalized TCR therapies
5:00 pm Integrating Cutting-Edge Technologies, Including Multi-Omics & AIDriven Data, to Advance Potent Personalized TCR-Based Therapies
- Personalized TCRs are both achievable and practical, offering great potential to broaden patient populations
- Enhanced TCR targetability and potency through the integration of multi-omics data
- Leveraging AI to predict TCR-pMHC folding structures, guiding TCR specificity and enhancing target diversity